Akeso Biopharma通过全球药物临床开发的共享投资筹集250M元。 Akeso Biopharma raises $250M through share placement for global clinical development of drugs.
中国一家药物开发公司Akeso Biopharma通过股份安排筹集了约2.5亿美元,主要目的是加强其创新药物的全球临床开发努力。 Akeso Biopharma, a Chinese drug development firm, has raised around $250 million through a share placement, primarily aimed at enhancing its global clinical development efforts for its innovative drugs. 在这次交易之后,该公司的现金储备总额将达到约10.64亿美元。 Following this transaction, the company's cash reserves will total approximately $1.064 billion. 这笔资金将支持中国和国际市场核心产品的进步,加强Akeso在全球的竞争力。 The funding will support the advancement of core products in both Chinese and international markets, bolstering Akeso's competitiveness globally.